GET CONNECTED
   



Mommy Makeovers Get Leggy

More mothers looking to varicose vein treatments as a part of their rejuvenated look
Motherhood, without doubt, brings an immense amount of joy, unimaginable solace and everlasting bliss; yet it comes with a price. According to the American Society of Plastic Surgeons, more than 60 percent of mothers look to plastic surgery to bring their pre-baby figures back. These efforts are often referred to as "Mommy Makeovers," where women most commonly seek out tummy tucks and breast augmentation (or lifts) to bring back that younger look. But many moms are also looking to varicose vein treatments as a part of their Mommy Makeover experience.

"When some women have children, their veins can be affected. Varicosities can start to develop during pregnancy and get worse after childbirth," explained Dr. Nick Morrison, a Phoenix-based phlebologist and founder of the Morrison Vein Institute. "When it comes to a Mommy Makeover, they start to realize this procedure is as important a cosmetic detail as a tummy tuck or breast enhancement."

Pregnancy and your veins
For the roughly 20 million women with varicose veins, many are genetically predisposed. They are born with faulty vein valves that eventually fail and allow the blood to flow back down the leg instead of up toward the heart, as it should. This causes blood pooling and unsightly varicose veins. During pregnancy, as the uterus grows, pressure on the vena cava (the large vein on the right side of the body) also increases pressure on the leg veins. The added pressure on the venous system during pregnancy only increases a woman's chances of getting varicose veins.

"The great news is that there are surgical and non-surgical treatments that can help bring back healthy-looking legs. And it's a much shorter recovery time than a tummy tuck or breast surgery," Morrison added.

Regain confidence with minimal pain
Part of the reason vein treatments are now becoming popular for Mommy Makeovers is the relatively quick recovery and the minimal pain associated with the procedures. Painful vein stripping is a thing of the past. Instead, there are treatments like Endovenous Laser Ablation, or EVTA. This procedure uses Duplex ultrasound technology to guide a thin laser fiber that delivers pulsed heat to the diseased vein wall. This causes the vein to close and eliminates venous reflux at its source. EVTA brings little downtime for patients and only requires local anesthesia. And there's also little to no scarring. Sclerotherapy also uses Duplex ultrasound to guide foam injections into larger vein abnormalities to the exact location of the venous reflux, closing off the vein and allowing the deeper venous systems to take over the blood flow. This effective treatment also requires little downtime and no anesthesia.

Feel-good factor, precautions
Many moms are surprised to learn how light and ache-free their legs feel after treatment, Morrison added. But the vein specialist also likes to have a candid conversation about the patient's overall health goals before vein treatment, especially if the procedure is part of a Mommy Makeover.

"We ask questions about the other procedures a person is having done," he added. "Even with the great technology that's out there, having many procedures in small time window can slow down healing. We like to make sure the body is well-rested and capable of healing before we start treatment."

For more information about the latest treatments for your varicose veins or to schedule a vein checkup, visit Morrison Vein, call 480-860-6455 or email the Morrison Vein Institute at info@morrisonvein.com.



FDA Approves the VenaSeal(TM) Closure System for Treatment of Clinically Symptomatic Venous Reflux

(Thomson Reuters ONE via COMTEX) -- VenaSeal Closure System, a Next-Generation Chronic Venous Insufficiency Procedure with Demonstrated Safety and Effectiveness

DUBLIN - Feb. 24, 2015 - Medtronic plc today announced U.S. Food and Drug Administration approval for VenaSeal(TM) closure system, a minimally invasive procedure that uses a specially formulated medical adhesive to close lower superficial extremities such as the great saphenous vein in patients with symptomatic venous reflux.

Venous reflux disease, also known as chronic venous insufficiency, occurs when valves in the veins of the lower leg no longer function properly. This allows blood to flow backward, or reflux, resulting in enlarged, or varicose veins as well as other symptoms. If left untreated, the condition can progress and, in severe cases, can result in lifestyle-limiting lower leg pain, swelling, skin damage and ulcerations.

The VenaSeal procedure is the only non-tumescent, non-thermal, non-sclerosant procedure approved for use in the U.S. that uses a specially formulated medical adhesive that closes the vein. This unique approach may eliminate the risk of nerve injury that is sometimes associated with certain thermal-based procedures. The procedure is administered without the use of tumescent anesthesia, minimizing the need for multiple needle sticks. Patients also report minimal-to-no bruising post procedure.

"The VenaSeal system is an advanced varicose vein procedure that delivers results that are comparable to current methods," said Dr. Nick Morrison, national principal investigator of the VeClose Trial, Morrison Vein Institute, Scottsdale, Ariz. "As the patient does not require multiple injections of a local anesthetic (tumescent anesthesia), there is minimal to no bruising and patients are often able to quickly return to normal activities."

The VenaSeal procedure is shown to be safe and effective, with consistent results across three clinical trials. Closure rates in the first in human trial were 92 percent at 12 and 24 months, respectively. Results from the European Sapheon Closure System Observational ProspectivE (eSCOPE) study published in the Journal of Vascular Surgery demonstrate a cumulative closure rate of 92.9 percent and improvement in quality of life scores at 12 months. Additionally, the three month results of the VeClose pivotal study published in the Journal of Vascular Surgery in January continue to demonstrate safety and efficacy of the VenaSeal procedure with excellent closure rates of 98.9 percent.

"The FDA approval of the VenaSeal system strengthens our endoVenous portfolio, providing physicians and their patients with a non-tumescent treatment option," said Sandra Lesenfants, vice president and general manager of the endoVenous franchise in Medtronic's Aortic and Peripheral Vascular business. "The VenaSeal System, together with our Venefit(TM) procedure, provides physicians and patients with leading treatment options."

The VenaSeal system is currently approved in the U.S., Australia, Canada, Europe and Hong Kong, and more than 2,000 patients have been treated with the system. U. S. launch of the VenaSeal system is expected this spring.

ABOUT MEDTRONIC
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland is the global leader in medical technology -alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Morrison Vein Institute - Scottsdale, Tempe - (480) 860-6455 - (866) GRT-LEGS (5347)
Copyright 2001 - 2015 Morrison Vein Institute - All Rights Reserved.